AEZS News and Press, Aeterna Zentaris Inc. From 10/08/21

Drug development company Aeterna Zentaris (AEZS), specialized in oncology and endocrine, has made significant advancements in areas of unmet medical needs. But since its therapeutic and diagnostic products are still in their clinical and preclinical development stages, commercialization could...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips A few hot penny stocks are seeing major movement on Friday as shares ride higher on recent news. We’re jumping into those below to see why investors are so happy with those companies today. Source: Shutterstock ...

CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announce...

– Company continues to advance clinical and preclinical programs with its d iversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need – Strong balance sheet with current cash of a...

7 Hot Penny Stocks For Your Watch List This Week Here we are at the start of a brand new week in the stock market. Penny stocks are at the top of mind for thousands of traders right now. Thanks to the excitement surrounding them, these cheap stocks continue growing in popularity. There ...

– Dr. Levy is a well-established n euroimmunologist with extensive experience and expertise in the area of neuroimmunology, autoimmune and CNS disorders – Company continues to advance development of its AIM Biologicals ...

CHARLESTON, S.C., June 03, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic pr...

Aeterna Zentaris (TSX:AEZS) (NASDAQ:AEZS) is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The company’s lead product, Macimorelin, is the first and only United States (U.S.) Food and Drug Administration (FDA) ...

A $52-billion pain management market, a $14-billion antidepressant market, and a $4.5 trillion global wellness market are all coming together to make what could be a mega opportunity for a segment that few can ignore anymore… That segment is psychedelics… a...

Aeterna Zentaris (AEZS) has commenced the previously announced preclinical program to qualify macimorelin for clinical development as a potential treatment option for amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), the most common motor neuron disease.The preclinical development pr...